| __timestamp | Iovance Biotherapeutics, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 2704597 | 382096000000 |
| Thursday, January 1, 2015 | 15470000 | 345927000000 |
| Friday, January 1, 2016 | 28037000 | 312303000000 |
| Sunday, January 1, 2017 | 71615000 | 325441000000 |
| Monday, January 1, 2018 | 99828000 | 368298000000 |
| Tuesday, January 1, 2019 | 166023000 | 492381000000 |
| Wednesday, January 1, 2020 | 201727000 | 455833000000 |
| Friday, January 1, 2021 | 259039000 | 526087000000 |
| Saturday, January 1, 2022 | 294781000 | 633325000000 |
| Sunday, January 1, 2023 | 344077000 | 729924000000 |
| Monday, January 1, 2024 | 729924000000 |
Unleashing the power of data
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) expenses are a critical indicator of innovation and growth. Over the past decade, Takeda Pharmaceutical Company Limited and Iovance Biotherapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments.
From 2014 to 2023, Takeda's R&D expenses have shown a consistent upward trend, peaking at approximately $730 billion in 2023. This represents a remarkable 91% increase from their 2014 expenditure, underscoring Takeda's commitment to pioneering new treatments and therapies.
Conversely, Iovance Biotherapeutics has experienced a meteoric rise in R&D spending, growing from a modest $2.7 million in 2014 to $344 million in 2023. This exponential growth, over 12,600%, highlights Iovance's aggressive push towards innovation in cancer immunotherapy.
While Takeda's investments reflect a stable and robust approach, Iovance's rapid escalation signals a dynamic and ambitious strategy. Both companies, despite their different scales, are pivotal players in the pharmaceutical industry's future.
Research and Development Investment: Gilead Sciences, Inc. vs Iovance Biotherapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and CymaBay Therapeutics, Inc.
Analyzing R&D Budgets: Takeda Pharmaceutical Company Limited vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and Soleno Therapeutics, Inc.
Takeda Pharmaceutical Company Limited vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Innovation Spending: Takeda Pharmaceutical Company Limited and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and Travere Therapeutics, Inc.
Takeda Pharmaceutical Company Limited or Viridian Therapeutics, Inc.: Who Invests More in Innovation?
Analyzing R&D Budgets: Madrigal Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
Comparing Innovation Spending: Alkermes plc and Iovance Biotherapeutics, Inc.
Comparing Innovation Spending: Axsome Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Iovance Biotherapeutics, Inc.